British American Tobacco p.l.c. (BATS.L): analysis and signal as of September 4, 2026
In short
The displayed signal is weak on British American Tobacco (BATS.L), for a vote of 2/2. The main reason lies in the opposition between a positive technical verdict and a negative risks and sentiment verdict, in a tobacco sector not favored by the regime brief.
- Current signal
- weak (vote 2/2)
- Deterministic score
- +2.0 → signal expected by the scale : moderate (September 10, 2026)
- Layers
- fundamentals : neutral, price : positive, risks : negative
Triggered rules
| Rule | Weight |
|---|---|
| penalizes a high bankruptcy risk (Altman Z-Score in distress zone, < 1,8) | -3.0 |
| favors (GARP) a stock whose PEG is below 1, growth not yet paid for | +1.5 |
| favors robust fundamental health (high Piotroski F-Score) | +1.5 |
| favors a "fast grower" profile, high and durable earnings growth (> 20 %), to be cross-checked against the PEG | +1.0 |
| moderately favors an asset with robust operating profitability (RMW factor), cross-check with accounting quality (possible manipulation) | +0.5 |
| moderately favors a positive 12-1 month momentum (tailwind), BUT guardrail: costly rotation, long-term reversal, momentum crashes, a conviction signal, not a rotation trigger | +0.5 |
Thesis
The tobacco sector appears neither among the favored factors (seeds and artificial intelligence, electrification, energy, defensive healthcare) nor among the penalized ones (exports and automobiles, discretionary consumption, rate-sensitive stocks) of the 2026-09-03 regime. It therefore sits in a grey area, without a structural catalyst. The defensive profile with a high dividend remains compatible with a neutral Cboe risk regime. The technical layer shows a pullback of -6,8 % against the 50-session moving average and of -6,2 % against the 200-session moving average, which signals a consolidation without a break rather than a confirmed reversal. The positive verdict of the price and technical layer opposes the negative verdict of the risks and sentiment layer, while the fundamentals layer remains silent for lack of verified data. The relative weight of the brief, with a non-favored sector, keeps the aggregated verdict at a neutral level.
Bull case
The stock keeps a defensive profile appreciated by institutional investors. Intraday returns come out at +11,1 basis points per day, against -2,7 basis points per day overnight, with a cumulative intraday total of +68 % over two years. The price pulls back below its moving averages without a structural break. This configuration remains compatible with a tactical rebound in a support zone, in a neutral risk regime and without stress on the high-yield credit market.
Bear case
The tobacco sector remains structurally value-depressed. Cigarette volumes decline by -2 to -3 % per year in developed markets, and the transition to new products (NGP) happens at a lower margin. Regulatory monitoring by the FDA and the European Union continues. The EXPANSION brief favors growth, artificial intelligence, energy and defensive healthcare, without including tobacco. There are also an unquantified US litigation risk and an unhedged exposure to GBP and EUR currency moves.
Scenarios
The bullish scenario, with a probability of 30 %, describes a target of +15 % over 12 months, driven by a value rebound and a positive GLP-1 sector catalyst. The central scenario, with a probability of 50 %, expects a move within a range of plus or minus 5 % around the moving averages. The bearish scenario, with a probability of 20 %, corresponds to a maximum loss of -30 % in the event of major US litigation or an FDA regulatory shock on vaping.
Risks
The weak signal and the absence of verified data on the fundamentals justify a cautious reading. A close below the 200-session moving average, accompanied by confirmation from volumes, would invalidate the thesis. The stock shows a depressed value profile and has already suffered drawdowns greater than 30 % in 2023 and 2024, which illustrates the scale of possible corrections in this sector. The US litigation risk, unquantified, introduces uncertainty on the valuation.
Signal history (last 12 months)
| Date | Signal | New fact |
|---|---|---|
| weak (2/2) | No change since the previous analysis. |
Frequently asked questions
What is the displayed signal for British American Tobacco?
The displayed signal is weak, for a vote of 2/2. This weakness is explained by the opposition between a positive verdict from the price and technical layer and a negative verdict from the risks and sentiment layer. The fundamentals layer remains silent for lack of verified data, and the tobacco sector is not favored by the regime brief, which keeps the verdict at a low-conviction level.
Why is the tobacco sector not favored by the EXPANSION brief?
The EXPANSION brief targets growth, artificial intelligence, energy and defensive healthcare. Tobacco appears neither among these favored factors nor among the penalized ones, such as exports, automobiles or discretionary consumption. It finds itself in a grey area, without a structural catalyst. The sector is moreover value-depressed, with cigarette volumes declining by -2 to -3 % per year in developed markets.
What do the technical indicators show on this stock?
The price shows a pullback of -6,8 % against the 50-session moving average and of -6,2 % against the 200-session moving average. This decline remains a consolidation without a structural break. Intraday returns come out at +11,1 basis points per day, against -2,7 basis points per day overnight, with a cumulative intraday total of +68 % over two years.
What would invalidate the described thesis?
Invalidation would come through a close below the 200-session moving average, accompanied by confirmation from volumes. The current pullback is still read as a consolidation without a break. The weak signal and the silent fundamentals layer, for lack of verified data, also reinforce the need for technical confirmation before any more favorable reading of the stock.
What risks specifically weigh on this stock?
Three main risks stand out. An unquantified US litigation risk weighs on the valuation. Regulation remains a threat, notably an FDA shock on vaping. Finally, the exposure to GBP and EUR currency moves is not hedged, and the stock has already suffered drawdowns greater than 30 % in 2023 and 2024, a precedent to keep in mind for this value profile.
Sources
No official filing is attached to this stock in the database to date. The figures quoted above come from an automated arbitration: they have not been re-checked one by one.
Automated AI analysis: limitations and transparency
- This content is an automated analysis produced using artificial intelligence. Personal analysis for information purposes — no personalised investment advice. MMR content consists of general research. It does not take account of your financial circumstances, objectives or risk tolerance. Data, analyses and results, including those produced using artificial intelligence, may contain errors, be incomplete or become outdated. No return or outcome is guaranteed. All investments carry a risk of partial or total loss of capital. Past performance and simulations do not predict future results. Before making any decision, check information against original sources and, where necessary, consult an authorised professional. You remain responsible for your investment decisions. This notice does not exclude or limit any liability that cannot legally be excluded or limited.
- Tool and analysis: QDNA, Aurélien Ambert.
- Analysis (arbitration) completed on September 4, 2026; this page was completed on September 4, 2026 at 05:26 (UTC).
- Interests: no position in the stock analysed (BATS.L) is recorded in the data consulted on (UTC). This does not confirm the absence of holdings or other interests. The situation at the analysis publication date has not been reconstructed.
- This declaration covers only recorded positions in this stock; it is not an exhaustive verification of other interests or remuneration.
- Methodology: analysis chain, score formula and scale described on the public methodology page.
- Analysis horizon: 2035.
See also
- Neighbouring stock in the same sector: Coca-Cola Europacific Partners PLC (CCEP)
- All analysed stocks
- Public methodology